JCXH-212 / Immorna - LARVOL DELTA

A phase I study of a common neoantigen srRNA vaccine (JCXH-212) with or without toripalimab in patients with non-small cell lung cancer(NSCLC) (ESMO Asia 2024) - P1 | "Conclusions JCXH-212 monotherapy or in combination with toripalimab demonstrated a tolerable safety profile and induced neoantigen-specific T cell immune responses in patients with advanced NSCLC. Further investigation of JCXH-212 in combination with toripalimab may be conducted in NSCLC."

Clinical • P1 data • Tumor-specific neoantigens • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNG

Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute | Trial completion date: Apr 2024 ➔ Apr 2027 | Trial primary completion date: Jan 2024 ➔ Apr 2026

Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Evaluate the Safety and Tolerability of JCXH-212 Injection in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study to Evaluate the Safety and Tolerability of JCXH-212 Injection in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute

New P1 trial • Oncology • Solid Tumor